Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node positive early breast cancer

NICE's diagnostics guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34) makes recommendations on tumour profiling tests for oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer. This guidance will assess use of the tests for ER-positive, HER2-negative cancer that has spread to the…